The National Practice Benchmark for oncology, 2014 report on 2013 data.
The National Practice Benchmark (NPB) is a unique tool to measure oncology practices against others across the country in a way that allows meaningful comparisons despite differences in practice size or setting. In today's economic environment every oncology practice, regardless of business structure or affiliation, should be able to produce, monitor, and benchmark basic metrics to meet current business pressures for increased efficiency and efficacy of care. Although we recognize that the NPB survey results do not capture the experience of all oncology practices, practices that can and do participate demonstrate exceptional managerial capability, and this year those practices are recognized for their participation. In this report, we continue to emphasize the methodology introduced last year in which we reported medical revenue net of the cost of the drugs as net medical revenue for the hematology/oncology product line. The effect of this is to capture only the gross margin attributable to drugs as revenue. New this year, we introduce six measures of clinical data density and expand the radiation oncology benchmarks.
Oncology Metrics, a division of Flatiron Health, New York, NY etowle@oncomet.com.
Elaine L
EL
Towle
Oncology Metrics, a division of Flatiron Health, New York, NY.
Thomas R
TR
Barr
Oncology Metrics, a division of Flatiron Health, New York, NY.
James L
JL
Senese
D000970:Antineoplastic Agents / Q000191:economics; D019985:Benchmarking; D002201:Capital Expenditures; D003365:Costs and Cost Analysis; D004526:Efficiency; D006276:Health Facility Size / Q000191:economics / Q000592:standards; D006280:Health Workforce / Q000191:economics; D006801:Humans; D007182:Income; D008495:Medical Oncology / Q000191:economics / Q000592:standards*; D009369:Neoplasms / Q000188:drug therapy / Q000191:economics; D010607:Pharmacy Service, Hospital / Q000191:economics / Q000592:standards; D014481:United States
D000970:Antineoplastic Agents